Italia markets closed
Dow Jones
40.023,20 +19,61 (+0,05%) Nasdaq
16.793,40 +107,43 (+0,64%) Nikkei 225
39.069,68 +282,30 (+0,73%) EUR/USD
1,0864 -0,0008 (-0,08%) Bitcoin EUR
62.084,45 +482,19 (+0,78%) CMC Crypto 200
1.373,50 +19,08 (+1,41%)
NVCR Jul 2024 30.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 11:36AM EDT. Mercato aperto.
| Chiusura precedente | 0,5900 |
| Aperto | 0,9300 |
| Denaro | 1,2500 |
| Lettera | 1,4000 |
| Prezzo d'esercizio | 30,00 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 0,8000 - 1,4000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,19k |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.